Central Neuromodulators for Treating Functional GI Disorders: A Primer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28349992.
- Also identified by DOI 10.1038/ajg.2017.57.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined. Dosing, augmentation strategies, and treatment scenarios specifically for painful FGIDs, FD with PDS, and chronic nausea and vomiting syndrome are outlined.
Medical subject headings
- Antidepressive Agents, Tricyclic
- Gastrointestinal Diseases
- Neurotransmitter Agents